Targeting the abnormal expression of BET proteins in cancer cells has been the subject of intensive study in cancer research in the last decade, which has led to the successful development of multiple anticancer agents, such as small molecule inhibitor JQ1 and I-BET151 (5, 6). Here, DNER is linked to cancer.